Butopamine

Butopamine
Clinical data
Other names
  • LY-131126
  • (R,R)-Ractopamine
Drug classSympathomimetic; β-Adrenergic receptor agonist; Positive inotrope; Positive chronotrope
Identifiers
  • 4-[(3R)-3-[[(2R)-2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]butyl]phenol
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H23NO3
Molar mass301.386 g·mol−1
3D model (JSmol)
  • C[C@H](CCC1=CC=C(C=C1)O)NC[C@@H](C2=CC=C(C=C2)O)O
  • InChI=1S/C18H23NO3/c1-13(2-3-14-4-8-16(20)9-5-14)19-12-18(22)15-6-10-17(21)11-7-15/h4-11,13,18-22H,2-3,12H2,1H3/t13-,18+/m1/s1
  • Key:YJQZYXCXBBCEAQ-ACJLOTCBSA-N

Butopamine (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name LY-131126; also known as (R,R)-ractopamine) is a sympathomimetic agent, β-adrenergic receptor agonist, and positive inotrope of the phenethylamine family which was studied for treatment of heart failure but was never marketed. It is an analogue of dobutamine and is the (R,R)-enantiomer of ractopamine. Butopamine is not a catecholamine and is resistant to metabolism by catechol O-methyltransferase (COMT). In contrast to dobutamine, butopamine is orally active. In addition to its positive inotropic effects, butopamine has positive chronotropic effects.

References

  1. ↑ Elks J (2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer US. p. 199. ISBN 978-1-4757-2085-3. Retrieved 27 February 2025.
  2. 1 2 Morton IK, Hall JM (2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Netherlands. p. 58. ISBN 978-94-011-4439-1. Retrieved 27 February 2025.
  3. 1 2 3 4 5 Hess HJ (1981). Annual Reports in Medicinal Chemistry. Academic Press. p. 96. ISBN 978-0-08-058360-0. Retrieved 27 February 2025.
  4. 1 2 Chatterjee K (March 1985). "Recent advances in the management of chronic heart failure". Prim Care. 12 (1): 117–142. doi:10.1016/S0095-4543(21)01244-6. PMID 3846305.